The Delhi High Court has allowed Sun Pharmaceutical Industries Ltd. to manufacture and export its semaglutide-based drug, which is similar to Novo Nordisk’s Ozempic, while prohibiting its sale within India. The court’s order permits the company to supply the drug to international markets where patent restrictions do not apply, ensuring compliance with intellectual property rights.
During the proceedings, the court asked Sun Pharma to submit a formal affidavit within two weeks confirming that the drug will be exported only and not sold domestically. The company informed the court that production of the drug has already begun in its facilities.
This ruling follows previous cases involving other Indian pharmaceutical companies producing semaglutide generics, where the Delhi High Court allowed exports but barred domestic sales until pending patent disputes with Novo Nordisk are resolved. The judgment effectively enables Sun Pharma to participate in the global supply of semaglutide, while Indian patients must await either the expiration of patent protection or the conclusion of ongoing legal proceedings before accessing the drug locally.
The decision highlights the delicate balance between promoting access to affordable medicines in India and respecting international patent rights. Sun Pharma’s export authorization now opens opportunities in foreign markets, but the domestic rollout remains legally restricted.
The post Sun Pharma can manufacture and export semaglutide, but not sell in India: Delhi High Court appeared first on India Legal.